Nathan Gossai

More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling

Peter Bader, Emilia Salzmann‐Manrique, Adriana Balduzzi et al. · Blood Advances · 2019 · 103 citations · Full text

Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone

Nathan Gossai, Megan V. Hilgers, Lynda E. Polgreen et al. · Pediatric Blood & Cancer · 2015 · 76 citations

Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia

Amy K. Keating, Nathan Gossai, Christine L. Phillips et al. · Blood Advances · 2019 · 67 citations · Full text

Mixed-phenotype Acute Leukemia, Pathology, Hematological Malignancy +16

Report of a patient with a constitutional missense mutation in <i>SMARCB1</i>, Coffin–Siris phenotype, and schwannomatosis

Nathan Gossai, Jaclyn A. Biegel, Ludwine Messiaen et al. · American Journal of Medical Genetics Part A · 2015 · 43 citations

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium

Yana Pikman, Sarah K. Tasian, Maria Luisa Sulis et al. · Cancer Discovery · 2021 · 38 citations · Full text